Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Byrd

Showing results (571-580 of 1,058) with videos related to

Pageof 106
Sort By:
Journal of Pharmaceutical and Biomedical Analysis|October 8, 2013
Sensitive liquid chromatography/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissueYao Jiang, Jiang Wang, Darlene M Rozewski, et al.
Cancer Chemotherapy and Pharmacology|November 9, 2014
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignanciesEleonora Marostica, Juthamas Sukbuntherng, David Loury, et al.
Blood|January 25, 2005
Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistancePing-Hui Tseng, Ho-Pi Lin, Jiuxiang Zhu, et al.
Cancer|February 27, 2010
Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemiaNeil E Kay, Wenting Wu, Brian Kabat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2017
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of IbrutinibCameron J Turtle, Kevin A Hay, Laïla-Aïcha Hanafi, et al.
British Journal of Haematology|November 28, 2018
Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitorWilliam G Wierda, John C Byrd, Matthew S Davids, et al.
Leukemia & Lymphoma|September 11, 2013
Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemiaRebecca B Klisovic, William Blum, Zhongfa Liu, et al.
British Journal of Haematology|January 17, 2014
Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002David A Rizzieri, Jeffrey L Johnson, John C Byrd, et al.
Leukemia|July 16, 2022
Depth of response and progression-free survival in chronic lymphocytic leukemia patients treated with ibrutinibAudrey M Sigmund, Ying Huang, Amy S Ruppert, et al.
Blood|August 7, 2007
Nonstochastic pairing of immunoglobulin heavy and light chains expressed by chronic lymphocytic leukemia B cells is predicated on the heavy chain CDR3George F Widhopf, Craig J Goldberg, Traci L Toy, et al.
Pageof 106

Showing results (571-580 of 1,058) with videos related to

Sort By:
Pageof 106
Journal of Pharmaceutical and Biomedical Analysis|October 8, 2013
Sensitive liquid chromatography/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissueYao Jiang, Jiang Wang, Darlene M Rozewski, et al.
Cancer Chemotherapy and Pharmacology|November 9, 2014
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignanciesEleonora Marostica, Juthamas Sukbuntherng, David Loury, et al.
Blood|January 25, 2005
Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistancePing-Hui Tseng, Ho-Pi Lin, Jiuxiang Zhu, et al.
Cancer|February 27, 2010
Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemiaNeil E Kay, Wenting Wu, Brian Kabat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2017
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of IbrutinibCameron J Turtle, Kevin A Hay, Laïla-Aïcha Hanafi, et al.
British Journal of Haematology|November 28, 2018
Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitorWilliam G Wierda, John C Byrd, Matthew S Davids, et al.
Leukemia & Lymphoma|September 11, 2013
Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemiaRebecca B Klisovic, William Blum, Zhongfa Liu, et al.
British Journal of Haematology|January 17, 2014
Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002David A Rizzieri, Jeffrey L Johnson, John C Byrd, et al.
Leukemia|July 16, 2022
Depth of response and progression-free survival in chronic lymphocytic leukemia patients treated with ibrutinibAudrey M Sigmund, Ying Huang, Amy S Ruppert, et al.
Blood|August 7, 2007
Nonstochastic pairing of immunoglobulin heavy and light chains expressed by chronic lymphocytic leukemia B cells is predicated on the heavy chain CDR3George F Widhopf, Craig J Goldberg, Traci L Toy, et al.
Pageof 106